Company Filing History:
Years Active: 2011-2013
Title: John-Philippe Surivet: Innovator in Antibacterial Compounds
Introduction
John-Philippe Surivet is a notable inventor based in Kembs, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antibacterial compounds. With a total of 2 patents, his work has the potential to impact the treatment of bacterial infections.
Latest Patents
Surivet's latest patents include innovative compounds that target bacterial infections. One of his notable inventions is related to oxazolidinone derivatives. This invention pertains to compounds of Formula (I), wherein U, V, W, R, R, A, and G are defined in the description. These compounds are associated with pharmaceutically acceptable salts and are intended for use in the manufacture of a medicament for the prevention or treatment of bacterial infections. Another significant patent involves tricyclic antibiotics, which are antibacterial compounds of formula (I). In this case, R represents H, F, or hydroxymethyl, and B is absent. The components Y, Y, Y, and Z independently represent CH or N, while Q represents O or S. E represents phenyl, which is mono- or di-substituted with halogen substituents.
Career Highlights
John-Philippe Surivet is currently associated with Actelion Pharmaceuticals Ltd. His work at this company has allowed him to focus on the development of innovative solutions for combating bacterial infections. His expertise in medicinal chemistry has positioned him as a valuable asset in the pharmaceutical industry.
Collaborations
Surivet has collaborated with notable colleagues, including Christian N Hubschwerlen and Georg Rueedi. These collaborations have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
John-Philippe Surivet's contributions to the field of antibacterial compounds highlight his innovative spirit and dedication to improving healthcare. His patents reflect a commitment to addressing critical medical challenges, particularly in the fight against bacterial infections.